Kulshrestha Randeep Kumar, Vinjamuri Sobhan, England Andrew, Nightingale Julie, Hogg Peter
Queensland X-Ray, Cairns Private Hospital, Cairns, Australia
Department of Nuclear Medicine, Royal Liverpool Hospital, Liverpool, United Kingdom; and.
J Nucl Med Technol. 2016 Dec;44(4):217-222. doi: 10.2967/jnmt.116.176859. Epub 2016 Sep 15.
We describe the role of F-sodium fluoride (F-NaF) PET/CT bone scanning in the staging of breast and prostate cancer. F-NaF PET was initially utilized as a bone scanning agent in the 1960s and early 1970s, however, its use was restricted by the then-available γ-cameras. The advent of hybrid PET/CT cameras in the late 1990s has shown a resurgence of interest in its use and role. After a brief introduction, this paper describes the radiopharmaceutical properties, dosimetry, pharmacokinetics, and mechanism of uptake of F-NaF. The performance of F-NaF PET/CT is then compared with that of conventional bone scintigraphy using current evidence from the literature. Strengths and weaknesses of F-NaF PET/CT imaging are highlighted. Clinical examples of improved accuracy of diagnosis and impact on patient management are illustrated. Limitations of F-NaF PET/CT imaging are outlined.
我们描述了氟-氟化钠（F-NaF）PET/CT骨扫描在乳腺癌和前列腺癌分期中的作用。F-NaF PET最初在20世纪60年代和70年代初被用作骨扫描剂，然而，其应用受到当时可用的γ相机的限制。20世纪90年代末混合型PET/CT相机的出现，使其在应用和作用方面重新引起了人们的兴趣。在简要介绍之后，本文描述了F-NaF的放射性药物特性、剂量学、药代动力学和摄取机制。然后，利用文献中的现有证据，将F-NaF PET/CT的性能与传统骨闪烁显像的性能进行比较。突出了F-NaF PET/CT成像的优缺点。举例说明了诊断准确性提高的临床实例及其对患者管理的影响。概述了F-NaF PET/CT成像的局限性。
